Clinical Trials

Wet (Neovascular) Age-Related Macular Degeneration

PULSAR Study

Description: Clinical trial evaluating whether the use of a higher dose of aflibercept, which is already FDA-approved for treatment of wet age-related macular degeneration (AMD), will allow for less frequent eye injections in wet AMD.

Full Title: Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration

Sponsor: Bayer Pharmaceuticals

Principal Investigator: Scott McClintic, MD

Study Coordinator: Marina Sprauer, LPN

Status: Actively Enrolling

Dry (Atrophic) Age-Related Macular Degeneration

TELESCOPE Study

Description: Patients with advanced dry AMD provide a saliva sample to screen for AMD-associated genes. If targeted AMD-associated genes are present, subjects may be invited to participate in other trials, including a more extensive natural history study called SCOPE.

Sponsor: Gyroscope Therapeutics

Principal Investigator: Monica Michelotti, MD

Study Coordinator: Marina Sprauer, LPN

Status: Actively Enrolling

Retinal Vein Occlusion

BEACON Study

Description: Phase 3 clinical trial evaluating whether a new, long-acting anti-VEGF medication (KSI-301) will provide better vision outcomes and allow for less frequent eye injections when compared to an existing medication (aflibercept) in the treatment of macular edema associated with retinal vein occlusion.

Full Title: A Study to Evaluate the Efficacy and Safety of KSI-301 Compared to Aflibercept in Participants with Macular Edema Secondary to Retinal Vein Occlusion (RVO)

Sponsor: Kodiak Sciences, Inc.

Principal Investigator: Andrew Westfall, MD

Study Coordinator: Marina Sprauer, LPN

Status: Actively Enrolling

Diabetic Retinopathy

GLIMMER Study

Description: Phase 3 clinical trial evaluating whether a new, long-acting anti-VEGF medication (KSI-301) will provide better vision outcomes and allow for less frequent eye injections when compared to an existing medication (aflibercept) in the treatment of diabetic macular edema.

Full Title: A Study to Evaluate the Efficacy and Safety of KSI-301 Compared to Aflibercept in Participants with Diabetic Macular Edema (DME)

Sponsor: Kodiak Sciences, Inc.

Principal Investigator: Andrew Westfall, MD

Study Coordinator: Marina Sprauer, LPN

Status: Actively Enrolling

 

DRCR (Diabetic Retinopathy Clinical Research network)

Principal Investigator: Scott McClintic, MD

Study Coordinator: Marina Sprauer, LPN

Status: Not currently enrolling

Completed Clinical Trials at Retina Consultants

COPERNICUS Study

A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor Trap-Eye in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion.

VIEW1

A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration.

VIEW1 Extension Study

An Open-label, Long-term, Safety and Tolerability Extension Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration.